United Therapeutics Corporation $UTHR Shares Purchased by Simplify Asset Management Inc.

Simplify Asset Management Inc. boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 43.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,251 shares of the biotechnology company’s stock after purchasing an additional 10,412 shares during the period. United Therapeutics makes up 0.3% of Simplify Asset Management Inc.’s holdings, making the stock its 13th biggest holding. Simplify Asset Management Inc.’s holdings in United Therapeutics were worth $20,310,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of UTHR. Leuthold Group LLC increased its stake in United Therapeutics by 41.4% during the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after acquiring an additional 3,126 shares during the last quarter. UBS Group AG raised its position in United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after purchasing an additional 70,445 shares during the period. Perpetual Ltd acquired a new position in shares of United Therapeutics in the 4th quarter valued at $1,059,000. SG Americas Securities LLC lifted its stake in shares of United Therapeutics by 88.6% in the 4th quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock valued at $13,136,000 after purchasing an additional 12,663 shares during the last quarter. Finally, Brookstone Capital Management grew its holdings in shares of United Therapeutics by 25.4% during the 4th quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock worth $3,227,000 after purchasing an additional 1,342 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $552.56, for a total value of $4,586,248.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $24,960,240.32. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $554.61, for a total transaction of $5,268,795.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,468,914.93. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 632,718 shares of company stock valued at $356,533,651. 8.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on UTHR shares. Raymond James Financial started coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Bank of America increased their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Finally, HC Wainwright boosted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Stock Performance

UTHR stock opened at $555.91 on Friday. The company has a market capitalization of $23.60 billion, a PE ratio of 20.52, a P/E/G ratio of 1.82 and a beta of 0.58. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The business’s fifty day moving average price is $558.34 and its 200 day moving average price is $527.84.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $6.63 earnings per share. Research analysts predict that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics agreed to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestone payments. The deal adds Thymmune’s preclinical thymic cell therapy THY-100 and expands UTHR’s regenerative medicine platform, especially for organ transplantation tolerance and related immune disorders. Article Title
• Positive Sentiment: Analysts continue to view UTHR favorably overall, with the stock carrying a Moderate Buy consensus rating. That suggests the market still sees upside support despite recent volatility and insider sales. Article Title
• Neutral Sentiment: CEO Martine A. Rothblatt and EVP Paul Mahon both sold shares this week, which can create a modest overhang for investor sentiment, though these sales were disclosed and do not necessarily signal a change in the company’s fundamentals. Article Title
• Neutral Sentiment: United Therapeutics recently reported quarterly results that missed analyst expectations on both earnings and revenue, so investors may still be weighing the company’s strong long-term growth strategy against softer near-term execution. Article Title

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.